Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 11
2003 5
2004 12
2005 7
2006 8
2007 4
2008 9
2009 3
2010 8
2011 8
2012 11
2013 11
2014 2
2015 5
2016 6
2017 4
2018 7
2019 5
2020 4
2021 10
2022 6
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: rieckmann p. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. Among authors: rieckmann p. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P. Giovannoni G, et al. Among authors: rieckmann p. Mult Scler. 2018 Oct;24(12):1594-1604. doi: 10.1177/1352458517727603. Epub 2017 Sep 5. Mult Scler. 2018. PMID: 28870107 Free article. Clinical Trial.
Improving MS patient care.
Rieckmann P. Rieckmann P. J Neurol. 2004 Sep;251 Suppl 5:v69-v73. doi: 10.1007/s00415-004-1511-z. J Neurol. 2004. PMID: 15549359 Review.
Treating multiple sclerosis with monoclonal antibodies.
Buttmann M, Rieckmann P. Buttmann M, et al. Among authors: rieckmann p. Expert Rev Neurother. 2008 Mar;8(3):433-55. doi: 10.1586/14737175.8.3.433. Expert Rev Neurother. 2008. PMID: 18345973 Review.
Expert opinion on the use of cladribine tablets in clinical practice.
Sørensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, Wiendl H, Yamout B, Salloukh H, Rieckmann P. Sørensen PS, et al. Among authors: rieckmann p. Ther Adv Neurol Disord. 2020 Jun 24;13:1756286420935019. doi: 10.1177/1756286420935019. eCollection 2020. Ther Adv Neurol Disord. 2020. PMID: 32636933 Free PMC article. Review.
Multiple sclerosis in the Arabian Gulf countries: a consensus statement.
Bohlega S, Inshasi J, Al Tahan AR, Madani AB, Qahtani H, Rieckmann P. Bohlega S, et al. Among authors: rieckmann p. J Neurol. 2013 Dec;260(12):2959-63. doi: 10.1007/s00415-013-6876-4. Epub 2013 Mar 17. J Neurol. 2013. PMID: 23504049 Free PMC article. Review.
137 results